Caldesmon (phospho Ser759) Polyclonal Antibody

    • Catalog No.:YP1084
    • Applications:IHC;IF;ELISA
    • Reactivity:Human;Mouse;Rat
      • Target:
      • Caldesmon
      • Fields:
      • >>Vascular smooth muscle contraction
      • Gene Name:
      • CALD1
      • Protein Name:
      • Caldesmon
      • Human Gene Id:
      • 800
      • Human Swiss Prot No:
      • Q05682
      • Immunogen:
      • The antiserum was produced against synthesized peptide derived from human Caldesmon around the phosphorylation site of Ser759. AA range:725-774
      • Specificity:
      • Phospho-Caldesmon (S759) Polyclonal Antibody detects endogenous levels of Caldesmon protein only when phosphorylated at S759.
      • Formulation:
      • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
      • Source:
      • Polyclonal, Rabbit,IgG
      • Dilution:
      • IHC 1:100 - 1:300. ELISA: 1:10000.. IF 1:50-200
      • Purification:
      • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
      • Concentration:
      • 1 mg/ml
      • Storage Stability:
      • -15°C to -25°C/1 year(Do not lower than -25°C)
      • Other Name:
      • CALD1;CAD;CDM;Caldesmon;CDM
      • Molecular Weight(Da):
      • high molecular weight (predominantly in smooth muscles) (120-150 KD) and a low molecular weight (60-90KD)
      • Background:
      • This gene encodes a calmodulin- and actin-binding protein that plays an essential role in the regulation of smooth muscle and nonmuscle contraction. The conserved domain of this protein possesses the binding activities to Ca(2+)-calmodulin, actin, tropomyosin, myosin, and phospholipids. This protein is a potent inhibitor of the actin-tropomyosin activated myosin MgATPase, and serves as a mediating factor for Ca(2+)-dependent inhibition of smooth muscle contraction. Alternative splicing of this gene results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2008],
      • Function:
      • domain:The N-terminal part seems to be a myosin/calmodulin-binding domain, and the C-terminal a tropomyosin/actin/calmodulin-binding domain. These two domains are separated by a central helical region in the smooth-muscle form.,function:Actin- and myosin-binding protein implicated in the regulation of actomyosin interactions in smooth muscle and nonmuscle cells (could act as a bridge between myosin and actin filaments). Stimulates actin binding of tropomyosin which increases the stabilization of actin filament structure. In muscle tissues, inhibits the actomyosin ATPase by binding to F-actin. This inhibition is attenuated by calcium-calmodulin and is potentiated by tropomyosin. Interacts with actin, myosin, two molecules of tropomyosin and with calmodulin. Also play an essential role during cellular mitosis and receptor capping.,PTM:In non-muscle cells, phosphorylation by CDC2 during mit
      • Subcellular Location:
      • Cytoplasm, cytoskeleton . Cytoplasm, myofibril . Cytoplasm, cytoskeleton, stress fiber . On thin filaments in smooth muscle and on stress fibers in fibroblasts (nonmuscle). .
      • Expression:
      • High-molecular-weight caldesmon (isoform 1) is predominantly expressed in smooth muscles, whereas low-molecular-weight caldesmon (isoforms 2, 3, 4 and 5) are widely distributed in non-muscle tissues and cells. Not expressed in skeletal muscle or heart.
      • Products Images
      • Immunohistochemical analysis of paraffin-embedded human Breast cancer. 1, Antibody was diluted at 1:200(4° overnight). 2, Tris-EDTA,pH9.0 was used for antigen retrieval. 3,Secondary antibody was diluted at 1:200(room temperature, 45min).